{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:54:05Z","timestamp":1790009645745,"version":"4.0.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004168","name":"Universit\u00e4t zu L\u00fcbeck","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004168","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Complement-mediated myocardial and vascular injury is a hallmark of ST-elevation myocardial infarction (STEMI). Dysregulated activation of complement component C5 has been implicated in endothelial dysfunction, exacerbated inflammatory responses, and progressive vascular damage during acute ischemia. Experimental data suggest that antagonizing the C5a\u2013C5aR1 axis may attenuate these effects, but clinical evidence regarding the impact of established C5 inhibitors during STEMI remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To investigate real-world cardiovascular and thromboembolic outcomes associated with C5 inhibition during STEMI, a propensity score-matched retrospective cohort study using the TriNetX Global Collaborative Network was performed. 174 patients with STEMI who had received Eculizumab or Ravulizumab for pre-existing complement-mediated disorders (paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, neuromyelitis optica, or myasthenia gravis) prior to the index event were compared with 174 matched patients without C5-inhibitor exposure. Outcomes were assessed at 30 days and 365 days after STEMI and included all-cause mortality, stroke or transient ischemic attack (TIA), arrhythmia, thrombotic disorders, major adverse circulatory events (MACE), acute kidney injury (AKI), and cardiomyopathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At 365 days, C5-inhibited patients demonstrated significantly higher risks of death (21.7% vs. 15.8;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05), stroke\/TIA (12.9% vs. 6.8%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05), thrombotic disorders (23.8% vs. 11.3%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), MACE (36.8% vs. 22.8%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and AKI (61.1% vs. 22.5%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Cardiomyopathy rates were comparable between groups. Arrhythmia occurred less frequently in the C5-inhibition cohort (30.3% vs. 37.4%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Similar patterns were observed at 30 days, with significantly increased risks for thrombotic disorders, MACE, and AKI in the C5-inhibited group. Hazard ratios confirmed elevated risks for most cardiovascular and thromboembolic outcomes at both time points.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this global real-world cohort, prior treatment with Eculizumab or Ravulizumab was associated with increased mortality and heightened cardiovascular and thromboembolic risk following STEMI. These findings underscore the need for careful clinical consideration of ongoing C5-inhibitor therapy in the acute management of STEMI and highlight the importance of prospective studies to clarify the mechanistic and clinical implications of complement blockade in acute myocardial ischemia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-026-05752-6","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T06:29:19Z","timestamp":1774247359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Complement C5 inhibition with eculizumab or ravulizumab is associated with increased cardiovascular and thromboembolic risk after ST-elevation myocardial infarction: a propensity-matched global retrospective cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Carl","family":"Vahldieck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"5752_CR1","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1161\/CIRCRESAHA.111.243162","volume":"110","author":"NG Frangogiannis","year":"2012","unstructured":"Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circ Res. 2012;110:159\u201373.","journal-title":"Circ Res"},{"key":"5752_CR2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.imlet.2018.06.006","volume":"200","author":"L Bavia","year":"2018","unstructured":"Bavia L, et al. Complement activation in acute myocardial infarction: An early marker of inflammation and tissue injury? Immunol Lett. 2018;200:18\u201325.","journal-title":"Immunol Lett"},{"key":"5752_CR3","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1161\/01.CIR.0000087447.12918.85","volume":"108","author":"CB Granger","year":"2003","unstructured":"Granger CB, et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation. 2003;108:1184\u201390.","journal-title":"Circulation"},{"key":"5752_CR4","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1161\/01.CIR.0000087404.53661.F8","volume":"108","author":"KW Mahaffey","year":"2003","unstructured":"Mahaffey KW, et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the Complement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation. 2003;108:1176\u201383.","journal-title":"Circulation"},{"key":"5752_CR5","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1097\/TXD.0000000000000881","volume":"5","author":"AK Bongoni","year":"2019","unstructured":"Bongoni AK, et al. Complement-mediated damage to the glycocalyx plays a role in renal ischemia-reperfusion Injury in Mice. Transpl Direct. 2019;5:e341.","journal-title":"Transpl Direct"},{"key":"5752_CR6","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1161\/01.CIR.97.22.2259","volume":"97","author":"AP Vakeva","year":"1998","unstructured":"Vakeva AP, et al. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation. 1998;97:2259\u201367.","journal-title":"Circulation"},{"key":"5752_CR7","doi-asserted-by":"publisher","first-page":"1426526","DOI":"10.3389\/fimmu.2024.1426526","volume":"15","author":"C Vahldieck","year":"2024","unstructured":"Vahldieck C, et al. Dysregulated complement activation during acute myocardial infarction leads to endothelial glycocalyx degradation and endothelial dysfunction via the C5a:C5a-Receptor1 axis. Front Immunol. 2024;15:1426526.","journal-title":"Front Immunol"},{"key":"5752_CR8","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1172\/JCI117430","volume":"94","author":"KE Foreman","year":"1994","unstructured":"Foreman KE, et al. C5a-induced expression of P-selectin in endothelial cells. J Clin Invest. 1994;94:1147\u201355.","journal-title":"J Clin Invest"},{"key":"5752_CR9","first-page":"7540","volume":"34","author":"P Shivshankar","year":"2020","unstructured":"Shivshankar P, Li Y-D, Mueller-Ortiz SL, Wetsel RA. In response to complement anaphylatoxin peptides C3a and C5a, human vascular endothelial cells migrate and mediate the activation of B-cells and polarization of T-cells. FASEB J Off Publ Fed Am Soc Exp Biol. 2020;34:7540\u201360.","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"key":"5752_CR10","doi-asserted-by":"publisher","first-page":"110081","DOI":"10.1016\/j.intimp.2023.110081","volume":"118","author":"M Ghosh","year":"2023","unstructured":"Ghosh M, Rana S. The anaphylatoxin C5a: Structure, function, signaling, physiology, disease, and therapeutics. Int Immunopharmacol. 2023;118:110081.","journal-title":"Int Immunopharmacol"},{"key":"5752_CR11","first-page":"3325","volume":"134","author":"SR Marder","year":"1985","unstructured":"Marder SR, Chenoweth DE, Goldstein IM, Perez HD. Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a and C5a des Arg. J Immunol Baltim Md 1950. 1985;134:3325\u201331.","journal-title":"J Immunol Baltim Md 1950"},{"key":"5752_CR12","first-page":"Doc20","volume":"8","author":"MN Busche","year":"2010","unstructured":"Busche MN, Stahl GL. Role of the complement components C5 and C3a in a mouse model of myocardial ischemia and reperfusion injury. Ger Med Sci GMS E-J. 2010;8:Doc20.","journal-title":"Ger Med Sci GMS E-J"},{"key":"5752_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jama.297.1.43","volume":"297","author":"APEXAMI Investigators","year":"2007","unstructured":"Investigators APEXAMI, et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA. 2007;297:43\u201351.","journal-title":"JAMA"},{"key":"5752_CR14","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","volume":"124","author":"RA Brodsky","year":"2014","unstructured":"Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124:2804\u201311.","journal-title":"Blood"},{"key":"5752_CR15","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s40265-013-0147-7","volume":"73","author":"GM Keating","year":"2013","unstructured":"Keating GM. Eculizumab: a review of its use in atypical haemolytic uraemic syndrome. Drugs. 2013;73:2053\u201366.","journal-title":"Drugs"},{"key":"5752_CR16","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology. 2021;96:114\u201322.","journal-title":"Neurology"},{"key":"5752_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","volume":"271","author":"T K\u00fcmpfel","year":"2024","unstructured":"K\u00fcmpfel T, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. J Neurol. 2024;271:141\u201376.","journal-title":"J Neurol"},{"key":"5752_CR18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s40265-019-01068-2","volume":"79","author":"K McKeage","year":"2019","unstructured":"McKeage K, Ravulizumab. First Global Approval. Drugs. 2019;79:347\u201352.","journal-title":"Drugs"},{"key":"5752_CR19","doi-asserted-by":"publisher","first-page":"ooad035","DOI":"10.1093\/jamiaopen\/ooad035","volume":"6","author":"MB Palchuk","year":"2023","unstructured":"Palchuk MB, et al. A global federated real-world data and analytics platform for research. JAMIA Open. 2023;6:ooad035.","journal-title":"JAMIA Open"},{"key":"5752_CR20","doi-asserted-by":"publisher","first-page":"101619","DOI":"10.1016\/j.eclinm.2022.101619","volume":"53","author":"W Wang","year":"2022","unstructured":"Wang W, Wang C-Y, Wang S-I, Wei JC-C. Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: A retrospective cohort study from the TriNetX US collaborative networks. eClinicalMedicine. 2022;53:101619.","journal-title":"eClinicalMedicine"},{"key":"5752_CR21","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40262-019-00742-8","volume":"58","author":"KL Wijnsma","year":"2019","unstructured":"Wijnsma KL, et al. Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab. Clin Pharmacokinet. 2019;58:859\u201374.","journal-title":"Clin Pharmacokinet"},{"key":"5752_CR22","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/bjh.16711","volume":"191","author":"R de Peffault","year":"2020","unstructured":"de Peffault R, et al. Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies. Br J Haematol. 2020;191:476\u201385.","journal-title":"Br J Haematol"},{"key":"5752_CR23","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jacc.2016.10.060","volume":"69","author":"MC Elze","year":"2017","unstructured":"Elze MC, et al. Comparison of Propensity Score Methods and Covariate Adjustment: Evaluation in 4 Cardiovascular Studies. J Am Coll Cardiol. 2017;69:345\u201357.","journal-title":"J Am Coll Cardiol"},{"key":"5752_CR24","first-page":"2825","volume":"12","author":"F Pedregosa","year":"2011","unstructured":"Pedregosa F, et al. Scikit-learn: Machine Learning in Python. Mach Learn PYTHON J Mach Learn Res. 2011;12:2825\u201330.","journal-title":"Mach Learn PYTHON J Mach Learn Res"},{"key":"5752_CR25","first-page":"154","volume":"33","author":"MA Rothstein","year":"2005","unstructured":"Rothstein MA. Currents in contemporary ethics. Research privacy under HIPAA and the common rule. J Law Med Ethics J Am Soc Law Med Ethics. 2005;33:154\u20139.","journal-title":"J Law Med Ethics J Am Soc Law Med Ethics"},{"key":"5752_CR26","doi-asserted-by":"publisher","first-page":"1385491","DOI":"10.3389\/fmed.2024.1385491","volume":"11","author":"B Gershater","year":"2024","unstructured":"Gershater B, et al. Differential risks of psoriatic arthritis development in patients with varied psoriasis manifestations: a sex- and ethnicity-specific analysis. Front Med. 2024;11:1385491.","journal-title":"Front Med"},{"key":"5752_CR27","doi-asserted-by":"publisher","first-page":"105485","DOI":"10.1016\/j.ebiom.2024.105485","volume":"111","author":"K Kridin","year":"2025","unstructured":"Kridin K, et al. Biological, as opposed to classic antipsoriatic drug or apremilast, treatment mitigates the risk of death and cardiovascular disease in psoriasis. EBioMedicine. 2025;111:105485.","journal-title":"EBioMedicine"},{"key":"5752_CR28","doi-asserted-by":"publisher","first-page":"1516433","DOI":"10.3389\/fendo.2025.1516433","volume":"16","author":"S Mousavi","year":"2025","unstructured":"Mousavi S, et al. Large-scale analysis highlights obesity as a risk factor for chronic, non-communicable inflammatory diseases. Front Endocrinol. 2025;16:1516433.","journal-title":"Front Endocrinol"},{"key":"5752_CR29","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/bjh.12347","volume":"162","author":"P Hillmen","year":"2013","unstructured":"Hillmen P, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013;162:62\u201373.","journal-title":"Br J Haematol"},{"key":"5752_CR30","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1097\/TP.0000000000003302","volume":"104","author":"J Kusakabe","year":"2020","unstructured":"Kusakabe J, et al. Complement 5 Inhibition Ameliorates Hepatic Ischemia\/reperfusion Injury in Mice, Dominantly via the C5a-mediated Cascade. Transplantation. 2020;104:2065\u201377.","journal-title":"Transplantation"},{"key":"5752_CR31","doi-asserted-by":"publisher","first-page":"300","DOI":"10.2215\/CJN.00620117","volume":"13","author":"V Brocklebank","year":"2018","unstructured":"Brocklebank V, Wood KM, Kavanagh D. Thrombotic microangiopathy and the kidney. Clin J Am Soc Nephrol CJASN. 2018;13:300\u201317.","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"5752_CR32","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41581-021-00424-4","volume":"17","author":"F Fakhouri","year":"2021","unstructured":"Fakhouri F, Fr\u00e9meaux-Bacchi V. Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. Nat Rev Nephrol. 2021;17:543\u201353.","journal-title":"Nat Rev Nephrol"},{"key":"5752_CR33","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJMra0902814","volume":"361","author":"M Noris","year":"2009","unstructured":"Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361:1676\u201387.","journal-title":"N Engl J Med"},{"key":"5752_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.70251","author":"L Gerischer","year":"2025","unstructured":"Gerischer L, et al. Inhibition of classical and alternative complement pathway by ravulizumab and eculizumab. Ann Clin Transl Neurol. 2025. https:\/\/doi.org\/10.1002\/acn3.70251.","journal-title":"Ann Clin Transl Neurol"},{"key":"5752_CR35","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.athoracsur.2003.08.054","volume":"77","author":"SK Shernan","year":"2004","unstructured":"Shernan SK, et al. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. Ann Thorac Surg. 2004;77:942\u20139. discussion 949\u2013950.","journal-title":"Ann Thorac Surg"},{"key":"5752_CR36","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jtcvs.2010.08.035","volume":"142","author":"PK Smith","year":"2011","unstructured":"Smith PK, et al. Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials. J Thorac Cardiovasc Surg. 2011;142:89\u201398.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"5752_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-025-11044-x","author":"J Ratajczak","year":"2025","unstructured":"Ratajczak J, et al. Complosome activation after myocardial infarction in a murine model of permanent LAD ligation. Stem Cell Rev Rep. 2025. https:\/\/doi.org\/10.1007\/s12015-025-11044-x.","journal-title":"Stem Cell Rev Rep"},{"key":"5752_CR38","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1161\/01.RES.83.8.860","volume":"83","author":"K Yasojima","year":"1998","unstructured":"Yasojima K, Schwab C, McGeer EG, McGeer PL. Human heart generates complement proteins that are upregulated and activated after myocardial infarction. Circ Res. 1998;83:860\u20139.","journal-title":"Circ Res"},{"key":"5752_CR39","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1161\/01.CIR.81.1.156","volume":"81","author":"M Yasuda","year":"1990","unstructured":"Yasuda M, et al. The complement system in ischemic heart disease. Circulation. 1990;81:156\u201363.","journal-title":"Circulation"},{"key":"5752_CR40","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1002\/stem.1743","volume":"32","author":"M Wysoczynski","year":"2014","unstructured":"Wysoczynski M, et al. Complement component 3 is necessary to preserve myocardium and myocardial function in chronic myocardial infarction. Stem Cells Dayt Ohio. 2014;32:2502\u201315.","journal-title":"Stem Cells Dayt Ohio"},{"key":"5752_CR41","doi-asserted-by":"publisher","first-page":"606407","DOI":"10.3389\/fcell.2020.606407","volume":"8","author":"C-W Vogel","year":"2020","unstructured":"Vogel C-W. The role of complement in myocardial infarction reperfusion injury: an underappreciated therapeutic target. Front Cell Dev Biol. 2020;8:606407.","journal-title":"Front Cell Dev Biol"},{"key":"5752_CR42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cca.2006.06.010","volume":"374","author":"TV Arumugam","year":"2006","unstructured":"Arumugam TV, et al. Complement mediators in ischemia-reperfusion injury. Clin Chim Acta Int J Clin Chem. 2006;374:33\u201345.","journal-title":"Clin Chim Acta Int J Clin Chem"},{"key":"5752_CR43","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ajpath.2022.12.009","volume":"193","author":"C Vahldieck","year":"2023","unstructured":"Vahldieck C, et al. Endothelial glycocalyx and cardiomyocyte damage is prevented by recombinant syndecan-1 in acute myocardial infarction. Am J Pathol. 2023;193:474\u201392.","journal-title":"Am J Pathol"},{"key":"5752_CR44","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/ejh.13783","volume":"109","author":"AG Kulasekararaj","year":"2022","unstructured":"Kulasekararaj AG, et al. Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2\u2010year results from two pivotal phase 3 studies. Eur J Haematol. 2022;109:205\u201314.","journal-title":"Eur J Haematol"},{"key":"5752_CR45","doi-asserted-by":"crossref","unstructured":"Hok KD et al. Functional Roles of the Complement Immune System in Cardiac Inflammation and Hypertrophy. Int J Mol Sci. 2025;26:9931.","DOI":"10.3390\/ijms26209931"},{"key":"5752_CR46","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1161\/ATVBAHA.107.160580","volume":"28","author":"SP Kastl","year":"2008","unstructured":"Kastl SP, et al. In human macrophages the complement component C5a induces the expression of oncostatin M via AP-1 activation. Arterioscler Thromb Vasc Biol. 2008;28:498\u2013503.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"5752_CR47","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1055\/a-2434-4905","volume":"125","author":"Y Asare","year":"2025","unstructured":"Asare Y, et al. Cardiac repair after myocardial infarction is controlled by a complement C5a receptor 1-driven signaling cascade. Thromb Haemost. 2025;125:508\u201312.","journal-title":"Thromb Haemost"},{"key":"5752_CR48","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.3390\/biomedicines11112924","volume":"11","author":"C Vahldieck","year":"2023","unstructured":"Vahldieck C, et al. Prolonged door-to-balloon time leads to endothelial glycocalyx damage and endothelial dysfunction in patients with ST-elevation myocardial infarction. Biomedicines. 2023;11:2924.","journal-title":"Biomedicines"},{"key":"5752_CR49","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.4110\/in.2025.25.e32","volume":"25","author":"A Shadid","year":"2025","unstructured":"Shadid A, et al. Enigmatic roles of complement anaphylatoxin signaling in health and disease. Immune Netw. 2025;25:e32.","journal-title":"Immune Netw"},{"key":"5752_CR50","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s00277-022-04903-x","volume":"101","author":"RSM Wong","year":"2022","unstructured":"Wong RSM, et al. Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria. Ann Hematol. 2022;101:1971\u201386.","journal-title":"Ann Hematol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-05752-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05752-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05752-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:40:51Z","timestamp":1781642451000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-05752-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5752"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-05752-6","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study involving human data were conducted in accordance with the ethical standards of the responsible institutional and national research committees and with the 1964 Declaration of Helsinki and its later amendments. This study was based exclusively on de-identified electronic health record data obtained from the TriNetX Global Collaborative Network. The TriNetX platform provides access only to aggregated and de-identified patient data and operates in compliance with the de-identification standards defined in \u00a7 164.514(a) of the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule. The de-identification process has been formally certified by a qualified expert as specified in \u00a7 164.514(b)(1) of the HIPAA Privacy Rule. Because the analysis involved only anonymized secondary data and no direct interaction with human participants, the requirement for informed consent was waived. The Ethics Committee of the University of L\u00fcbeck confirmed that no additional ethical approval was required for this study design.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"298"}}